We can’t show the full text here under this license. Use the link below to read it at the source.
Weight maintenance on cost‐effective antiobesity medications after 1 year of GLP‐1 receptor agonist therapy: a real‐world study
Keeping weight off with affordable anti-obesity medicines after 1 year of GLP-1 treatment in real life
AI simplified
Abstract
At 12 months, patients who transitioned to generic lost an average of 18.3% of their body weight from baseline.
- Patients had a mean baseline BMI of 36.4 kg/m.
- After transitioning to generic antiobesity medications, patients maintained a mean BMI of 27.9 kg/m at 12 and 18 months.
- Further follow-up indicated a total average weight loss of 25.5% compared to the initial visit.
- The findings suggest that older-generation antiobesity medications may effectively support weight maintenance after initial weight loss with .
AI simplified
Key numbers
18.3%
Average Weight Loss at 12 Months
Percentage weight loss from baseline after 12 months on .
25.5%
Total Average Weight Loss
Percentage weight loss compared to initial visit after 18 months.
27.9 kg/m²
Mean BMI at 18 Months
Mean body mass index of patients at 18 months post-transition.